<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACYCLOVIR- acyclovir suspension </strong><br>Hi-Tech Pharmacal Co., Inc.<br></p></div>
<h1>Acyclovir Oral Suspension, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_01450d42-a220-49a2-b5a2-74066c3a9d39"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Acyclovir is a synthetic nucleoside analogue active against herpesviruses.</p>
<p>Each teaspoonful (5 mL) of acyclovir oral suspension, USP, for oral administration, contains 200 mg of acyclovir and the inactive ingredients artificial banana flavor, carboxymethylcellulose sodium, glycerin, methylparaben 0.1% (added as a preservative), microcrystalline cellulose, propylparaben 0.02% (added as a preservative), purified water, and sorbitol.</p>
<p>Acyclovir is a white, crystalline powder with the molecular formula C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">5</span>O<span class="Sub">3</span> and a molecular weight of 225. The maximum solubility in water at 37°C is 2.5 mg/mL. The pka’s of acyclovir are 2.27 and 9.25.</p>
<p>The chemical name of acyclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- 6H-purin-6-one; it has the following structural formula:</p>
<div class="Figure">
<img alt="Acyclovir Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62bdcf22-51f3-4c81-9bd4-a2dc48bec580&amp;name=449d2a92-17d6-46a8-90dd-bfaa2463f071-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_410b176e-9002-44a6-a03c-cd24fe9cc410"></a><a name="section-1.1"></a><p></p>
<h2>VIROLOGY:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0cfed689-7771-4e8c-9dec-b2875c894b58"></a><a name="section-1.1.1"></a><p></p>
<h3>Mechanism of Antiviral Action:</h3>
<p class="First">Acyclovir is a synthetic purine nucleoside analogue with <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus (VZV).</p>
<p>The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. <span class="Italics">In vitro</span>, acyclovir triphosphate stops replication of herpes viral DNA. This is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared with VZV is due to its more efficient phosphorylation by the viral TK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4b0455f4-134f-4579-99d3-e05e3fd9a28a"></a><a name="section-1.1.2"></a><p></p>
<h3>Antiviral Activities:</h3>
<p class="First">The quantitative relationship between the <span class="Italics">in vitro</span> susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (IC<span class="Sub">50</span>), vary greatly depending upon a number of factors. Using plaque-reduction assays, the IC<span class="Sub">50</span> against herpes simplex virus isolates ranges from 0.02 to 13.5 mcg/mL for HSV-1 and from 0.01 to 9.9 mcg/mL for HSV-2. The IC<span class="Sub">50</span> for acyclovir against most laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates of VZV ranges from 0.12 to 10.8 mcg/mL. Acyclovir also demonstrates activity against the Oka vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of VZV with a mean IC<span class="Sub">50</span> of 1.35 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6aca99e8-a2aa-4b35-b953-5b58132253f3"></a><a name="section-1.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span>:</h3>
<p class="First">Resistance of HSV and VZV to acyclovir can result from qualitative and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of HSV and VZV with reduced susceptibility to acyclovir have been recovered from immunocompromised patients, especially with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. While most of the acyclovir-resistant mutants isolated thus far from immunocompromised patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have been isolated. TK-negative mutants may cause severe disease in infants and immunocompromised adults. The possibility of viral resistance to acyclovir should be considered in patients who show poor clinical response during therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f5291ff8-0167-4c3f-a39d-f67565569d95"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_92232a83-4396-4f61-b883-03b7cb7281fe"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First">The pharmacokinetics of acyclovir after oral administration have been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex or <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Acyclovir pharmacokinetic parameters are summarized in Table 1.</p>
<a name="id_984aa916-0a08-471d-abb0-bfdac81c5e6a"></a><table border="single" width="0.000">
<caption><span>Table 1: Acyclovir Pharmacokinetic Characteristics (Range)</span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">Parameter</td>
<td align="center" valign="top">Range</td>
</tr>
<tr>
<td align="left" valign="top"> Plasma protein binding</td>
<td align="center" valign="top">9% to 33%</td>
</tr>
<tr>
<td align="left" valign="top"> Plasma elimination half-life</td>
<td align="center" valign="top">2.5 to 3.3 hr</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"> Average oral bioavailability</td>
<td class="Botrule" align="center" valign="top">10% to 20%*</td>
</tr>
</tbody>
</table>
<p>*Bioavailability decreases with increasing dose.</p>
<p>In one multiple-dose, cross-over study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2. The decrease in bioavailability is a function of the dose and not the dosage form.</p>
<a name="id_cb2d9893-1724-4f1a-96f1-5bc41efad775"></a><table border="single" width="0.000">
<caption><span>Table 2: Acyclovir Peak and Trough Concentrations at Steady State</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">Parameter</td>
<td class="Toprule" align="center" valign="top">200 mg</td>
<td class="Toprule" align="center" valign="top">400 mg</td>
<td align="center" valign="top">800 mg</td>
</tr>
<tr>
<td align="center" valign="top">C<span class="Sup">ss</span><span class="Sub">max</span>
</td>
<td align="center" valign="middle">0.83 mcg/mL</td>
<td align="center" valign="middle">1.21 mcg/mL</td>
<td align="center" valign="middle">1.61 mcg/mL</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">C<span class="Sup">ss</span><span class="Sub">trough</span>
</td>
<td class="Botrule" align="center" valign="middle">0.46 mcg/mL</td>
<td class="Botrule" align="center" valign="middle">0.63 mcg/mL</td>
<td class="Botrule" align="center" valign="middle">0.83 mcg/mL</td>
</tr>
</tbody>
</table>
<p>There was no effect of food on the absorption of acyclovir (n=6); therefore, acyclovir oral suspension, USP may be administered with or without food.</p>
<p>The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a4a403d-52bb-446f-9282-17b82e7203f7"></a><a name="section-2.2"></a><p></p>
<h2>Special Populations:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07939100-4dce-4b5f-9fb5-4b7f3ca5e9fc"></a><a name="section-2.2.1"></a><p></p>
<h3>Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>:</h3>
<p class="First">The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function (see <a href="#i4i_dosage_admin_id_4e8488b4-2f98-43b0-aebe-24d85f4fc132">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8999b785-83e0-405f-ae64-9f7e8e3de9ae"></a><a name="section-2.2.2"></a><p></p>
<h3>Geriatrics:</h3>
<p class="First">Acyclovir plasma concentrations are higher in geriatric patients compared with younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_precautions_id_1d182829-1d34-4a99-a47c-2f15fd53d690">PRECAUTIONS</a>: Geriatric Use).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6935f3d0-8008-4493-824c-1e4ffde81f44"></a><a name="section-2.2.3"></a><p></p>
<h3>Pediatrics:</h3>
<p class="First">In general, the pharmacokinetics of acyclovir in pediatric patients is similar to that of adults. Mean half-life after oral doses of 300 mg/m<span class="Sup">2</span> and 600 mg/m<span class="Sup">2</span> in pediatric patients aged 7 months to 7 years was 2.6 hours (range 1.59 to 3.74 hours).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf9e882b-c8eb-4066-b838-4520af8317ea"></a><a name="section-2.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f80e158-36bc-4a67-8c06-63d9b6e4351d"></a><a name="section-2.4"></a><p></p>
<h2>Clinical Trials:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_010edd53-1c61-4e1e-a44c-4d06c45cde42"></a><a name="section-2.4.1"></a><p></p>
<h3>Initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</h3>
<p class="First">Double-blind, placebo-controlled studies have demonstrated that orally administered acyclovir significantly reduced the duration of acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and duration of lesion healing. The duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and new lesion formation was decreased in some patient groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe43169c-077b-4e3f-8f5b-973e71b5aaf6"></a><a name="section-2.4.2"></a><p></p>
<h3>Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</h3>
<p class="First">Double-blind, placebo-controlled studies in patients with frequent recurrences (6 or more episodes per year) have shown that orally administered acyclovir given daily for 4 months to 10 years prevented or reduced the frequency and/or severity of recurrences in greater than 95% of patients.</p>
<p>In a study of patients who received orally administered acyclovir 400 mg twice daily for 3 years, 45%, 52%, and 63% of patients remained free of recurrences in the first, second, and third years, respectively. Serial analyses of the 3-month recurrence rates for the patients showed that 71% to 87% were recurrence free in each quarter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42df2d26-abff-487c-bf13-5712f25c8491"></a><a name="section-2.4.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</h3>
<p class="First">In a double-blind, placebo-controlled study of immunocompetent patients with localized cutaneous zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, acyclovir (800 mg 5 times daily for 10 days) shortened the times to lesion <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>, healing, and complete cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and reduced the duration of viral shedding and the duration of new lesion formation.</p>
<p>In a similar double-blind, placebo-controlled study, acyclovir (800 mg 5 times daily for 7 days) shortened the times to complete lesion <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>, healing, and cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; reduced the duration of new lesion formation; and reduced the prevalence of localized zoster-associated <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> (<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, or <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>).</p>
<p>Treatment was begun within 72 hours of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> onset and was most effective if started within the first 48 hours.</p>
<p>Adults greater than 50 years of age showed greater benefit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f9e0fdf-b6ab-40c3-bf47-479612ec5b9a"></a><a name="section-2.4.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</h3>
<p class="First">Three randomized, double-blind, placebo-controlled trials were conducted in 993 pediatric patients aged 2 to 18 years with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. All patients were treated within 24 hours after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In 2 trials, acyclovir was administrated at 20 mg/kg 4 times daily (up to 3,200 mg per day) for 5 days. In the third trial, doses of 10, 15, or 20 mg/kg were administered 4 times daily for 5 to 7 days. Treatment with acyclovir shortened the time to 50% healing; reduced the maximum number of lesions; reduced the median number of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>; decreased the median number of residual lesions on day 28; and decreased the proportion of patients with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> by day 2. Treatment with acyclovir did not affect <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus-specific humoral or cellular immune responses at 1 month or 1 year following treatment.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_078fd197-ea6a-4932-9783-751b2a729dc1"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0011e88-3569-435c-919d-ac6932c095d2"></a><a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</h2>
<p class="First">Acyclovir oral suspension, USP is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_014e8267-3158-4318-ac3e-cf6c8ecaecd3"></a><a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</h2>
<p class="First">Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9222008-ad8b-41f8-a956-82710489522c"></a><a name="section-3.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</h2>
<p class="First">Acyclovir oral suspension, USP is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> (<span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1f21c807-fd3c-4448-b06b-4cc71cd5dee5"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Acyclovir is contraindicated for patients who develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to acyclovir or valacyclovir.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_0fdc501e-d02c-40eb-a42f-3bc3a21652b0"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Acyclovir is intended for oral ingestion only. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, in some cases resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been observed with acyclovir therapy (see <a href="#i4i_adverse_effects_id_2dfff462-3eaa-4d70-97c4-79c817057fde">ADVERSE REACTIONS</a>: Observed During Clinical Practice and <a href="#i4i_overdosage_id_32b15309-c118-4cc4-a38c-f10fb68482af">OVERDOSAGE:</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS), which has resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has occurred in immunocompromised patients receiving acyclovir therapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1d182829-1d34-4a99-a47c-2f15fd53d690"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Dosage adjustment is recommended when administering acyclovir to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_dosage_admin_id_4e8488b4-2f98-43b0-aebe-24d85f4fc132">DOSAGE AND ADMINISTRATION</a>). Caution should also be exercised when administering acyclovir to patients receiving potentially nephrotoxic agents since this may increase the risk of renal dysfunction and/or the risk of reversible central nervous system symptoms such as those that have been reported in patients treated with intravenous acyclovir. Adequate hydration should be maintained.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_19bb0539-2ff2-4b16-a8dc-17d642135985"></a><a name="section-6.1"></a><p></p>
<h2>Information for patients</h2>
<p class="First">Patients are instructed to consult with their physician if they experience severe or troublesome adverse reactions, they become pregnant or intend to become pregnant, they intend to breastfeed while taking orally administered acyclovir, or they have any other questions.</p>
<p>Patients should be advised to maintain adequate hydration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be19ba3c-96fa-461f-a4c2-0d4698e2f38c"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</h3>
<p class="First">There are no data on treatment initiated more than 72 hours after onset of the zoster <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Patients should be advised to initiate treatment as soon as possible after a diagnosis of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3622320-9e7c-4ff3-a1be-3e52f17e64f7"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Infections:</h3>
<p class="First">Patients should be informed that acyclovir is not a cure for <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. There are no data evaluating whether acyclovir will prevent transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. Because <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span> can also be transmitted in the absence of symptoms through asymptomatic viral shedding. If medical management of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> recurrence is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9017324a-863f-47aa-b135-8aeb8d027b17"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> in otherwise healthy children is usually a self-limited disease of mild to moderate severity. Adolescents and adults tend to have more severe disease. Treatment was initiated within 24 hours of the typical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in the controlled studies, and there is no information regarding the effects of treatment begun later in the disease course.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_c27e4fae-b8ba-48dd-9852-5652d122eeb0"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">See <a href="#i4i_clinical_pharmacology_id_f5291ff8-0167-4c3f-a39d-f67565569d95">CLINICAL PHARMACOLOGY</a>: Pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_17c8d62e-122e-4fd1-84cd-661d80120634"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 800 mg given orally 5 times a day (dosing appropriate for treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>) or 200 mg given orally 5 times a day (dosing appropriate for treatment of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>). Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see <a href="#i4i_clinical_pharmacology_id_f5291ff8-0167-4c3f-a39d-f67565569d95">CLINICAL PHARMACOLOGY</a>: Pharmacokinetics).</p>
<p>Acyclovir was tested in lifetime bioassays in rats and mice at single daily doses of up to 450 mg/kg administered by gavage. There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors. Maximum plasma concentrations were 3 to 6 times human levels in the mouse bioassay and 1 to 2 times human levels in the rat bioassay.</p>
<p>Acyclovir was tested in 16 <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> genetic toxicity assays. Acyclovir was positive in 5 of the assays.</p>
<p>Acyclovir did not impair fertility or reproduction in mice (450 mg/kg per day, PO) or in rats (25 mg/kg per day, SC). In the mouse study, plasma levels were 9 to 18 times human levels, while in the rat study, they were 8 to 15 times human levels. At higher doses (50 mg/kg per day, SC) in rats and rabbits (11 to 22 and 16 to 31 times human levels, respectively) implantation efficacy, but not litter size, was decreased. In a rat peri- and post-natal study at 50 mg/kg per day, SC, there was a statistically significant decrease in group mean numbers of corpora lutea, total implantation sites, and live fetuses.</p>
<p>No testicular abnormalities were seen in dogs given 50 mg/kg per day, IV for 1 month (21 to 41 times human levels) or in dogs given 60 mg/kg per day orally for 1 year (6 to 12 times human levels). <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span> and aspermatogenesis were observed in rats and dogs at higher dose levels.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_3d6fcd1b-8aca-4256-9ab5-930454e6f229"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_41321c1d-cdec-45a0-8455-71572be3f906"></a><a name="section-6.4.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First">Pregnancy Category B. Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg per day, PO), rabbit (50 mg/kg per day, SC and IV), or rat (50 mg/kg per day, SC). These exposures resulted in plasma levels 9 and 18, 16 and 106, and 11 and 22 times, respectively, human levels.</p>
<p>There are no adequate and well-controlled studies in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_83cccee4-7521-463d-b261-aabd2cde8a5a"></a><a name="section-6.5"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">Acyclovir concentrations have been documented in breast milk in 2 women following oral administration of acyclovir and ranged from 0.6 to 4.1 times corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg per day. Acyclovir should be administered to a nursing mother with caution and only when indicated.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_b18d1a14-df18-4e74-bd91-174bddd3fd61"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness of oral formulations of acyclovir in pediatric patients younger than 2 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_2511fd27-1777-4033-b7b0-f32444e1f02e"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">Of 376 subjects who received acyclovir in a clinical study of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> treatment in immunocompetent subjects greater than or equal to 50 years of age, 244 were 65 and over while 111 were 75 and over. No overall differences in effectiveness for time to cessation of new lesion formation or time to healing were reported between geriatric subjects and younger adult subjects. The duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing was longer in patients 65 and over. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> were reported more frequently in elderly subjects. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events. With respect to CNS adverse events observed during clinical practice, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> were reported more frequently in elderly patients (see <a href="#i4i_clinical_pharmacology_id_f5291ff8-0167-4c3f-a39d-f67565569d95">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_adverse_effects_id_2dfff462-3eaa-4d70-97c4-79c817057fde">ADVERSE REACTIONS</a>: Observed During Clinical Practice, and <a href="#i4i_dosage_admin_id_4e8488b4-2f98-43b0-aebe-24d85f4fc132">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_2dfff462-3eaa-4d70-97c4-79c817057fde"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf9c778f-351c-48f7-bead-4fc75050eaa1"></a><a name="section-7.1"></a><p></p>
<h2>Herpes Simplex:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b8551835-aa8a-4b3f-bb5e-517352ec96ad"></a><a name="section-7.1.1"></a><p></p>
<h3>Short-Term Administration:</h3>
<p class="First">The most frequent adverse events reported during clinical trials of treatment of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> with acyclovir 200 mg administered orally 5 times daily every 4 hours for 10 days were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 8 of 298 patient treatments (2.7%). <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurred in 2 of 287 (0.7%) patients who received placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ce5cefb-3efa-4451-9ac5-65796f079ac2"></a><a name="section-7.1.2"></a><p></p>
<h3>Long-Term Administration:</h3>
<p class="First">The most frequent adverse events reported in a clinical trial for the prevention of recurrences with continuous administration of 400 mg (two 200-mg capsules) 2 times daily for 1 year in 586 patients treated with acyclovir were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (4.8%) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.4%). The 589 control patients receiving intermittent treatment of recurrences with acyclovir for 1 year reported <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.7%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2.4%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.2%).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f4a0088-e5c5-4c7f-9480-1abbdb6dce83"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</h2>
<p class="First">The most frequent adverse event reported during 3 clinical trials of treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>) with 800 mg of oral acyclovir 5 times daily for 7 to 10 days in 323 patients was <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> (11.5%). The 323 placebo recipients reported <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> (11.1%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad7440f0-74e9-41de-84f8-78bbfde651f2"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</h2>
<p class="First">The most frequent adverse event reported during 3 clinical trials of treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> with oral acyclovir at doses of 10 to 20 mg/kg 4 times daily for 5 to 7 days or 800 mg 4 times daily for 5 days in 495 patients was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3.2%). The 498 patients receiving placebo reported <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.2%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a12f611-1286-44c7-b661-6bb11a2a0ff7"></a><a name="section-7.4"></a><p></p>
<h2>Observed During Clinical Practice:</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of acyclovir. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to acyclovir, or a combination of these factors.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90129088-d14e-416d-8d0a-a91bde897093"></a><a name="section-7.4.1"></a><p></p>
<h3>General:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1097c6e1-e912-4e12-9b62-d84174c89d8f"></a><a name="section-7.4.2"></a><p></p>
<h3>Nervous:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, decreased consciousness, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>. These symptoms may be marked, particularly in older adults or in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_precautions_id_1d182829-1d34-4a99-a47c-2f15fd53d690">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9755afe-2079-48b2-ba51-69151f9bd1f3"></a><a name="section-7.4.3"></a><p></p>
<h3>Digestive:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, gastrointestinal distress, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_607bdd83-ef63-41fe-b968-12291199a650"></a><a name="section-7.4.4"></a><p></p>
<h3>Hematologic and Lymphatic:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d56a6267-a1d9-404c-9e44-9defba855dd0"></a><a name="section-7.4.5"></a><p></p>
<h3>Hepatobiliary Tract and Pancreas:</h3>
<p class="First">Elevated liver function tests, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_164e8697-54c9-46f8-b236-c9b9e1c1ecb2"></a><a name="section-7.4.6"></a><p></p>
<h3>Musculoskeletal:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b682ff8d-0469-4e27-964e-9161cde7f1f9"></a><a name="section-7.4.7"></a><p></p>
<h3>Skin:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitive rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, Stevens- Johnson syndrome, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c080bcbb-f4e7-413d-a540-8a678f0090be"></a><a name="section-7.4.8"></a><p></p>
<h3>Special Senses:</h3>
<p class="First">Visual abnormalities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3722faa-96fd-4ae5-b421-34fdbfb9f5a4"></a><a name="section-7.4.9"></a><p></p>
<h3>Urogenital:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span> (may be associated with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>), elevated blood urea nitrogen, elevated creatinine, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (see <a href="#i4i_warnings_id_0fdc501e-d02c-40eb-a42f-3bc3a21652b0">WARNINGS</a>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_32b15309-c118-4cc4-a38c-f10fb68482af"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> involving ingestion of up to 20 g have been reported. Adverse events that have been reported in association with overdosage include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Overdosage has been reported following bolus injections or inappropriately high doses and in patients whose fluid and electrolyte balance were not properly monitored. This has resulted in elevated BUN and serum creatinine and subsequent <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. In the event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, the patient may benefit from hemodialysis until renal function is restored (see <a href="#i4i_dosage_admin_id_4e8488b4-2f98-43b0-aebe-24d85f4fc132">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4e8488b4-2f98-43b0-aebe-24d85f4fc132"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71a5eb89-5071-48c9-8a72-a36c85984d94"></a><a name="section-9.1"></a><p></p>
<h2>Acute Treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</h2>
<p class="First">800 mg every 4 hours orally, 5 times daily for 7 to 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8bf36970-0001-4dfb-9c59-035cefcd78d1"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74f05986-9905-4dbe-b28c-2d333af58008"></a><a name="section-9.2.1"></a><p></p>
<h3>Treatment of Initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</h3>
<p class="First">200 mg every 4 hours, 5 times daily for 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f476436a-3deb-4e18-a34d-337daa068f7a"></a><a name="section-9.2.2"></a><p></p>
<h3>Chronic Suppressive Therapy for Recurrent Disease:</h3>
<p class="First">400 mg 2 times daily for up to 12 months, followed by re-evaluation. Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily.</p>
<p>The frequency and severity of episodes of untreated <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> may change over time. After 1 year of therapy, the frequency and severity of the patient’s <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> infection should be re-evaluated to assess the need for continuation of therapy with acyclovir oral suspension.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f848a4fe-7036-483c-bd4b-2fd417850ba0"></a><a name="section-9.2.3"></a><p></p>
<h3>Intermittent Therapy:</h3>
<p class="First">200 mg every 4 hours, 5 times daily for 5 days. Therapy should be initiated at the earliest sign or symptom (prodrome) of recurrence.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7a7a016-2d3c-4267-aee3-fd4bcae6c179"></a><a name="section-9.3"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8dec8cf6-0918-4408-b531-55e5b4cbc64c"></a><a name="section-9.3.1"></a><p></p>
<h3>Children (2 years of age and older):</h3>
<p class="First">20 mg/kg <span class="Bold">per dose</span> orally 4 times daily (80 mg/kg per day) for 5 days. Children over 40 kg should receive the adult dose for <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ebcca061-d4a3-4644-a0cb-16a48d5b0556"></a><a name="section-9.3.2"></a><p></p>
<h3>Adults and Children over 40 kg:</h3>
<p class="First">800 mg 4 times daily for 5 days.</p>
<p>Intravenous acyclovir oral suspension is indicated for the treatment of varicellazoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in immunocompromised patients.</p>
<p>When therapy is indicated, it should be initiated at the earliest sign or symptom of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_44530ae9-db7e-4b90-b2f3-e000d639abb8"></a><a name="section-9.4"></a><p></p>
<h2>Patients With Acute or <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Renal Impairment</span>:</h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the dose of acyclovir oral suspension should be modified as shown in Table 3:</p>
<a name="id_5a7b1e6b-dc4f-4afb-98b4-13567426d85d"></a><table border="single" width="431.000">
<caption><span>Table 3: Dosage Modification for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<col width="26.7%">
<col width="23.2%">
<col width="21.3%">
<col width="28.8%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="middle">Normal Dosage Regimen</td>
<td class="Toprule" align="center" rowspan="2" valign="middle">
<p class="First">Creatinine </p>
<p>Clearance (mL/min/1.73 m<span class="Sup">2</span>)</p>
</td>
<td align="center" colspan="2" valign="middle">Adjusted Dosage Regimen</td>
</tr>
<tr>
<td align="center" valign="middle">
<p class="First">Dose</p>
<p>(mg)</p>
</td>
<td align="center" valign="middle"><p class="First">Dosing Interval</p></td>
</tr>
<tr>
<td align="left" valign="middle">200 mg every 4 hours</td>
<td align="center" valign="middle">
<p class="First">&gt; 10</p>
<p>0-10</p>
</td>
<td align="center" valign="middle">
<p class="First">200</p>
<p>200</p>
</td>
<td align="left" valign="middle">
<p class="First">every 4 hours, 5x daily</p>
<p>every 12 hours</p>
</td>
</tr>
<tr>
<td align="left" valign="middle">400 mg every 12 hours</td>
<td align="center" valign="middle">
<p class="First">&gt; 10</p>
<p>0-10</p>
</td>
<td align="center" valign="middle">
<p class="First">400</p>
<p>200</p>
</td>
<td align="left" valign="middle">
<p class="First">every 12 hours</p>
<p>every 12 hours</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">800 mg every 4 hours</td>
<td class="Botrule" align="center" valign="middle">
<p class="First">&gt; 25</p>
<p>10-25</p>
<p>0-10</p>
</td>
<td class="Botrule" align="center" valign="middle">
<p class="First">800</p>
<p>800</p>
<p>800</p>
</td>
<td class="Botrule" align="left" valign="middle">every 4 hours, 5x daily<p class="First">every 8 hours</p>
<p>every 12 hours</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3152f737-4043-4c2c-bb8e-95228c2696c0"></a><a name="section-9.5"></a><p></p>
<h2>Hemodialysis:</h2>
<p class="First">For patients who require hemodialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6af800cc-702c-48c6-8715-ef4bceb91bfe"></a><a name="section-9.6"></a><p></p>
<h2>Peritoneal Dialysis:</h2>
<p class="First">No supplemental dose appears to be necessary after adjustment of the dosing interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e741af88-5fa9-41d7-b163-4af790d9c25b"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Acyclovir oral suspension, USP (off-white, artificial banana-flavored) containing 200 mg acyclovir in each teaspoonful (5 mL) – Bottle of 1 pint (473 mL).</p>
<p><span class="Bold">Store at 20° - 25°C (68° to 77°F) [see USP Controlled Room Temperature].</span></p>
<p><br></p>
<p>Manufactured by:</p>
<p>Hi-Tech Pharmacal Co., Inc.</p>
<p>Amityville, NY 11701</p>
<p><br></p>
<p>Rev. 810:01 5/09</p>
<p>MG #19296</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b175b0e9-4f0c-4900-a014-f633a50947c6"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="Image of Container Label - 16 oz" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62bdcf22-51f3-4c81-9bd4-a2dc48bec580&amp;name=449d2a92-17d6-46a8-90dd-bfaa2463f071-02.jpg"></p>
<p><span class="Bold">ACYCLOVIR ORAL SUSPENSION, USP</span></p>
<p><span class="Bold">200 mg/5 mL</span></p>
<p><span class="Bold">Each teaspoonful (5 mL) contains:</span></p>
<p>Acyclovir..............................................200 mg</p>
<p>Methylparaben..........................................0.1%</p>
<p>Propylparaben.........................................0.02%</p>
<p>(Added as preservatives)</p>
<p><span class="Bold">USUAL DOSAGE:</span>  See package insert for dosage and full prescribing information.</p>
<p>Dispense in a tight container as defined in the USP.  Store at 20 to 25°C (68 to 77°F). [see USP Controlled Room Temperature].  Protect from light.</p>
<p><span class="Bold">Rx only</span></p>
<p> </p>
<p><span class="Bold">SHAKE WELL BEFORE USING</span></p>
<p> </p>
<p><span class="Bold">16 fl oz (473 mL)</span></p>
<p> </p>
<p>HI-TECH PHARMACAL CO., INC.</p>
<p>Amityville, NY  11701</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACYCLOVIR 		
					</strong><br><span class="contentTableReg">acyclovir suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50383-810</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACYCLOVIR</strong> (ACYCLOVIR) </td>
<td class="formItem">ACYCLOVIR</td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BANANA</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50383-810-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077026</td>
<td class="formItem">06/07/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hi-Tech Pharmacal Co., Inc.
							(101196749)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>449d2a92-17d6-46a8-90dd-bfaa2463f071</div>
<div>Set id: 62bdcf22-51f3-4c81-9bd4-a2dc48bec580</div>
<div>Version: 2</div>
<div>Effective Time: 20100616</div>
</div>
</div> <div class="DistributorName">Hi-Tech Pharmacal Co., Inc.</div></p>
</body></html>
